BMI Brazil Pharmaceuticals and Healthcare Report Q3 2011.pdf
《BMI Brazil Pharmaceuticals and Healthcare Report Q3 2011.pdf》由会员分享,可在线阅读,更多相关《BMI Brazil Pharmaceuticals and Healthcare Report Q3 2011.pdf(129页珍藏版)》请在三一文库上搜索。
1、Q3 2011 pharmaceuticals +8.4% in local currency terms and +22.2% in US dollar terms. Forecast up moderately from Q211 due to macroeconomic factors. ? Healthcare: BRL303.24bn (US$172.43bn) in 2010 to BRL334.70bn (US$214.55bn) in 2011; +10.4% in local currency terms and +24.4% in US dollar terms. For
2、ecast up moderately from Q211 due to macroeconomic factors. ? Medical devices: BRL6.62bn (US$3.76bn) in 2010 to BRL7.43bn (US$4.77bn) in 2011; +10.6% in local currency terms and +12.8% in US dollar terms. Forecast unchanged from Q211. Business Environment Rating: BMIs average Business Environment Ra
3、ting (BER) for the 17 Americas markets has increased from 48.8 out of 100 in Q211 to 49 in Q311. Brazils composite pharmaceutical rating is 61.8, remaining fourth in the Americas rank matrix. On a global basis, Brazil has risen through the ranks to 15th position, overtaking China, which previously h
4、ad equal score but has now dropped to 17th position among the top-scoring emerging markets. As a region, the Americas rank second only behind Western Europe in terms of attractiveness to multinational drugmakers. Key Trends however, Indias Ranbaxy had offered a generic version for only US$0.46 or US
5、$1.00 today. Farmanguinhoss pill will cost US$1.35 per unit. Brazil will pay Merck 1.5% from the proceeds of equity from the generic. BMI questions whether producing a generic version of a patented drug, which could be procured more cheaply elsewhere, essentially undermines the fundamentals of the o
6、riginal compulsory licence to save money. If associated import costs are indeed factored in to these prices, it appears that rather than avoiding intellectual property rights purely for cost saving measures, the government may have also used the TRIPS provisions to boost domestic production. The con
7、troversy over provisions for compulsory licensing came to the fore in 2004. Attention focused mainly on wrangling over patents on leading anti-retrovirals (ARVs), such as Kaletra (lopinavir + ritonavir), a protease inhibitor marketed by Abbott Laboratories. Brazil has operated an effective, free of
8、charge treatment programme for around 200,000 sufferers of HIV/AIDS. However, the government complained that three products marketed by US-based multinationals Mercks Stocrin, Gilead Sciencess Viread (tenofovir disoproxil fumarate) and Abbott Laboratories Kaletra accounted for 70% of the programmes
9、cost, which reached US$620mn in 2007. The government began manufacturing the schemes 13 other products in 1994, and state-controlled producers, including key manufacturer Farmanguinhos, started manufacturing raw materials for older generation therapies that have already come off patent. Notably in J
10、uly 2007, Abbott concluded a new deal with the Brazilian government for Kaletra that will see the drug sold at a 30% discount to the previous price. Brazils aggressive negotiating tactics with HIV/AIDS drugs producers has arguably paid off. One 2007 study claims the government has been able to save
11、US$1bn on ARVs between 2001 and 2005. According to PLoS Medicine, this was accomplished through a combination of agreeing prices with patent holders and local production of off-patent drugs. Patented ARVs make up almost 80% of Brazils total HIV/AIDS drug spend in value terms. Consequently, most of t
12、he cost savings were achieved through lower prices negotiated for patented ARVs, especially those whose patent is nearing expiry. Brazil Pharmaceuticals however, we note that the full 5.9% increase is unlikely to be realised across the full range of medicines. Supply chain specificities such as disc
13、ounts in addition to competitive manufacturer pricing strategies should result in a lower total market increase. Phytotherapeutic and homeopathic products are not affected by these regulations. Pharmaco-economic appraisal was brought back into the spotlight in Q209, as part of a session of public he
14、arings on health. With pharmaceutical spending representing an ever-growing burden on the government, the prospect of greater cost-effective spending assessments is considered by many to be essential. Antonio Barbosa da Silva, representative for the Office for Protection of Drug Users, indicated tha
15、t general overpricing of medicines in public tenders was a major issue and that in some cases prices are around 50% higher as a result. Pharmaceutical price variations between bioequivalent medicines in Brazil have been identified as vast in many cases, according to a January 2010 study by the Found
16、ation for Consumer Defence and Protection (Fundao Procon). The data show price variations as high as 1,415% between reference drugs and their generic equivalents, as well as wide differences within their respective groups. BMI believes that the well-publicised results should help further swing marke
17、t dynamics in favour of generic drugs, while they also highlight the wide levels of discounting below maximum prices. Brazil Pharmaceuticals however, given the current fiscal outlook and the lack of serious movement on this issue in recent years, any major reduction in taxes would appear unlikely at
18、 present. The Group Executive of the Industrial Health Complex (GECIS) began an extended meeting on May 28 2009, in which strategies to persuade states to reduce the tax burden on medicines will be considered. The Brazilian Pharmaceutical Industry Federation (Febrafarma) have been invited join the d
19、iscussions for a period to help analyse numbers and propose solutions. One of the proposals is to reduce the current average rate of 17.5% to 12%, or even to as low as 6%. Consumer prices are estimated to fall by around 9%, in line with an average tax reduction of 12%. One of the key challenges will
20、 be reaching convergent policies for the states, which have autonomy in applying tax rates. Most states charge 17%, while Rio de Janeiro charges the highest level of up to 19%. Brazil Pharmaceuticals however, we note that the new rules are not altogether unjust and bring regulations into line with b
21、etter established EU guidelines. Among the key changes to legislation, gifts or publicity in prescription forms have been prohibited. Stricter guidelines surrounding the communication of safety/product information will ensure television/radio adverts verbalise such warnings, while text sizes for war
22、nings must be at least 35% of the size of the largest font used in an advert. Television commercials for medicines are not allowed at a time when programmes aimed at children or adolescents are being aired. Free samples cannot be offered for drugs that do not require a prescription, while samples of
23、 contraceptives or antibiotics are only permitted if the company donates the full course of treatment. Pharmaceutical companies wishing to sponsor events or symposia must submit documentation to ANVISA three months prior to the event, stating the place, date and the categories of professionals invol
24、ved. Images of people taking drugs in adverts are prohibited while the participation of artists or celebrities is also heavily restricted. Limiting the use of celebrities in medicine advertising will dull a growing trend for manufacturers to use such icons as a means to raise brand profile. The effe
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- BMI Brazil Pharmaceuticals and Healthcare Report Q3 2011
链接地址:https://www.31doc.com/p-3731810.html